epilepsy

MRI of the brain
#Biotherapeutics #Bloom Science #epilepsy #Phase I trial

Live biotherapeutic could treat rare paediatric epilepsy

Bloom Science has completed enrolment of healthy adult participants as part of its Phase I clinical trial into BL-001 for Dravet syndrome, a rare paediatric epilepsy. BL-001 is an orally administered Live Biotherapeutic Product reverse translated from the positive clinical outcomes associated with the Ketogenic Diet… Read More

#News

Woman having epileptic fit
#CHMP #epilepsy #Europe #Neuroscience #Rare disease

Treatment for severe form of epilepsy approved in Europe

UCB’s Fintepla (fenfluramine) oral solution has been recommended for marketing authorisation in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare, severe form of epilepsy.  The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion… Read More

#News #Regulatory

MRI of the brain
#epilepsy #Mouse models #Neuroinflammation #Neuroscience

Neuroscientists discover new drug candidate for treating epilepsy

Neuroscientists have identified and developed a new drug candidate that has the potential to effectively treat temporal lobe epilepsy (TLE) by suppressing neuroinflammation.  Although symptomatic medications are available, one-third of TLE patients remain unresponsive to current treatment, so new drug targets are critically needed. Most of these… Read More

#News #Trending News

#Approvals #Drug approvals #epilepsy

Angelini Pharma’s anti-seizure medicine approved 

Angelini Pharma has announced that cenobamate, an oral anti-seizure medicine (ASM), is now available for use within NHS Scotland as a treatment for eligible adults with uncontrolled focal epilepsy. The Scottish Medicines Consortium (SMC) has accepted cenobamate for restricted use in adults with drug-resistant epilepsy as a second-line adjunctive… Read More

#News